Source comparison
CJC-1295 No DAC & Ipamorelin vs Tesamorelin Comparison
A 2022 analysis published in the Journal of Clinical Endocrinology & Metabolism found that growth hormone secretagogue combinations. Specifically CJC-1295 no DAC with ipamorelin. Produced 40–60% higher peak GH amplitude compared to single-agent protocols at eq
This comparison does not assign a generated winner or score.
- A 2022 analysis published in the Journal of Clinical Endocrinology & Metabolism found that growth hormone secretagogue combinations. Specifically CJC-1295 no DAC with ipamorelin. Produced 40–60% higher peak GH amplitude compared to single-agent protocols at equivalent dosing frequencies. The difference isn't just quantitative. The dual-peptide stack creates pulsatile secretion that mirrors endogenous circadian rhythm, while tesamorelin's sustained GHRH agonism produces steady-state elevation. Both approaches work. But they activate different receptor pathways, produce different pharmacokinetic profiles, and suit different research objectives.
- We've guided research teams through peptide selection across hundreds of protocols. The gap between choosing the right compound and choosing the most-marketed compound comes down to understanding receptor mechanisms, half-life kinetics, and how those variables map to specific experimental endpoints.
- What's the difference between CJC-1295 no DAC & ipamorelin versus tesamorelin for growth hormone research?
- CJC-1295 no DAC (also called modified GRF 1-29) is a growth hormone-releasing hormone (GHRH) analogue with a 30-minute half-life, typically paired with ipamorelin (a ghrelin receptor agonist with similar kinetics) to create synergistic pulsatile GH release. Tesamorelin is an FDA-approved GHRH analogue with selective action on visceral adipose tissue, originally indicated for HIV-associated lipodystrophy. The combination protocol targets dual pathways. GHRH and ghrelin receptors. While tesamorelin acts through GHRH receptors alone with longer duration per dose.